Artificial Intelligence in Drug Discovery and Development: Transforming Pharmaceutical Innovation
Drug Development Research · 2026-05 · 87 (3)
DOI: 10.1002/ddr.70281 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Drug Development Research, online erschienen am 19.04.2026. Verfasst von Mohd Shoab Ali und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutics, School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi, India. Hauptthemen laut MEDLINE: Drug Discovery, Artificial Intelligence, Drug Development. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 209 Literaturangaben. Gefördert von: Prince sattam bin Abdulaziz University, King Khalid University.
Abstract (Originalsprache)
Drug discovery remains a lengthy, costly, and high‐risk endeavor, often requiring over a decade from target identification to clinical translation. Artificial intelligence (AI) is reshaping this paradigm by enabling more efficient and accurate decision‐making across the discovery and development pipeline. Advances in machine learning, deep learning, and natural language processing now support target identification, hit finding, lead optimization, and drug repurposing with unprecedented speed and precision. AI‐driven insilico platforms further enhance early‐stage predictability by forecasting toxicity, pharmacokinetics, and developability, thereby reducing late‐stage attrition. This review critically examines the evolving role of AI in modern drug discovery and its expanding impact on pharmaceutical formulation development and personalized medicine. Collaborative models between AI developers and the pharmaceutical industries, essential for accelerating translational outcomes, are also highlighted. Finally, key challenges, including algorithmic transparency, data quality, interoperability, and regulatory acceptance, are discussed, along with future directions for harnessing AI's full potential in pharmaceutics.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pharmaceutics, School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi, India.
- Department of Pharmacology, College of Pharmacy, King Khalid University, Abha, Saudi Arabia.
- Department of Medical Laboratory, College of Applied Medical Sciences, Prince Sattam bin Abdulaziz University, Alkharj, Saudi Arabia.
- Graphic Era Hill University, Dehradun, India.
- School of Allied Medical Sciences, Lovely Professional University, Phagwara, Punjab, India.
- Faculty of Data Science and Information Technology, INTI International University, Nilai, Malaysia.
ORCID-Profile: Khang Wen Goh, Amirhossein Sahebkar, Prashant Kesharwani
Förderung
- Prince sattam bin Abdulaziz University
- King Khalid University
Zitieren
APA
Ali, M. S., Alqahtani, T., Shmrany, H. A., Gupta, G., Goh, K. W., Sahebkar, A., & Kesharwani, P. (2026). Artificial Intelligence in Drug Discovery and Development: Transforming Pharmaceutical Innovation. Drug Development Research, 87(3). https://doi.org/10.1002/ddr.70281
Vancouver
Ali MS, Alqahtani T, Shmrany HA, Gupta G, Goh KW, Sahebkar A, et al. Artificial Intelligence in Drug Discovery and Development: Transforming Pharmaceutical Innovation. Drug Development Research. 2026;87(3). doi:10.1002/ddr.70281
BibTeX
@article{Ali2026,
author = {Ali, Mohd Shoab and Alqahtani, Taha and Shmrany, Humood Al and Gupta, Garima and Goh, Khang Wen and Sahebkar, Amirhossein and Kesharwani, Prashant},
title = {Artificial Intelligence in Drug Discovery and Development: Transforming Pharmaceutical Innovation},
journal = {Drug Development Research},
year = {2026},
volume = {87},
number = {3},
doi = {10.1002/ddr.70281}
}
EUVIMED